BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Block & Leviton LLP, the law firm that filed the first securities class action against Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (NASDAQ:FOLD) is reminding investors that the deadline for seeking lead plaintiff status in the pending securities class action against Amicus is December 7, 2015. Investors who purchased Amicus securities between the expanded class period of March 19, 2015 and October 1, 2015 are eligible for inclusion in the action, and to be considered as lead plaintiffs.
The pending action charges that Amicus and certain of its officers misrepresented when Amicus would be able to file its New Drug Application with the Food and Drug Administration (“FDA”) for its oral small molecule pharmacological chaperone migalastat for the treatment of Fabry disease. Defendants publicly stated that, based on information provided by the FDA, the NDA was on track for filing in the fourth quarter of 2015. Yet on October 2, 2015, Amicus revealed that it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Amicus’ stock price plunged on this news, falling by 54% to $6.39 per share.
Amicus investors are reminded that if they wish to become a lead plaintiff, they must file a motion by December 7, 2015.
If you are interested in becoming a lead plaintiff, have questions about your legal rights, or if you have information relevant to this investigation, please contact attorneys Jake Walker or Jeffrey Block of Block & Leviton LLP at (617) 398-5600 or at Jake@blockesq.com or Jeff@blockesq.com. You may also retain counsel of your own choosing. Confidentiality for any whistleblowers or other persons with information relevant to the investigation is assured.
Block & Leviton represents investors for violations of securities laws as well as whistleblowing employees who provide information about their employers’ violations of law throughout the country. The firm’s lawyers have collectively been prosecuting securities cases for over 70 years, have recovered billions of dollars for investors and represent some of the nation’s largest institutional investors.
This notice may constitute attorney advertising.